FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES (Q2035463)

From EU Knowledge Graph
Revision as of 23:08, 24 January 2022 by DG Regio (talk | contribs) (‎Changed label, description and/or aliases in es, and other parts: Adding Spanish translations)
Jump to navigation Jump to search
Project Q2035463 in Italy
Language Label Description Also known as
English
FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES
Project Q2035463 in Italy

    Statements

    0 references
    186,460.21 Euro
    0 references
    372,920.43 Euro
    0 references
    50.0 percent
    0 references
    14 February 2017
    0 references
    13 October 2019
    0 references
    EVVIVAX S.R.L.
    0 references
    ISTITUTO SUPERIORE DI SANITA'
    0 references
    0 references
    0 references
    0 references

    41°53'35.95"N, 12°28'58.55"E
    0 references
    I VACCINI GENETICI HANNO MOLTEPLICI VANTAGGI POTENZIALI, TRA CUI IL TARGETING SPECIFICO, L'USO DI GENI MULTIPLI PER MIGLIORARE L'IMMUNITà, LA VELOCITà DI SINTESI E LA RIDUZIONE DEL RISCHIO RISPETTO AI VACCINI CONVENZIONALI. EVVIVAX Ê UNA NUOVA AZIENDA CH (Italian)
    0 references
    GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English)
    0 references
    LES VACCINS GÉNÉTIQUES PRÉSENTENT DE MULTIPLES AVANTAGES POTENTIELS, Y COMPRIS UN CIBLAGE SPÉCIFIQUE, L’UTILISATION DE GÈNES MULTIPLES POUR AMÉLIORER L’IMMUNITÉ, LA VITESSE DE SYNTHÈSE ET LA RÉDUCTION DES RISQUES PAR RAPPORT AUX VACCINS CONVENTIONNELS. EVVIVAX Ê UNE NOUVELLE ENTREPRISE QUI (French)
    16 December 2021
    0 references
    GENETISCHE VACCINS HEBBEN MEERDERE POTENTIËLE VOORDELEN, WAARONDER SPECIFIEKE TARGETING, HET GEBRUIK VAN MEERDERE GENEN OM DE IMMUNITEIT, DE SYNTHESESNELHEID EN DE RISICOVERMINDERING TE VERBETEREN IN VERGELIJKING MET CONVENTIONELE VACCINS. EVVIVAX Ê EEN NIEUW BEDRIJF DAT (Dutch)
    23 December 2021
    0 references
    GENETISCHE IMPFSTOFFE HABEN IM VERGLEICH ZU HERKÖMMLICHEN IMPFSTOFFEN MEHRERE POTENZIELLE VORTEILE, EINSCHLIESSLICH GEZIELTER TARGETING, DER VERWENDUNG MEHRERER GENE ZUR VERBESSERUNG DER IMMUNITÄT, DER SYNTHESEGESCHWINDIGKEIT UND DER RISIKOREDUKTION. EVVIVAX Ê EIN NEUES UNTERNEHMEN, DAS (German)
    24 December 2021
    0 references
    LAS VACUNAS GENÉTICAS TIENEN MÚLTIPLES BENEFICIOS POTENCIALES, INCLUYENDO LA ORIENTACIÓN ESPECÍFICA, EL USO DE MÚLTIPLES GENES PARA MEJORAR LA INMUNIDAD, LA VELOCIDAD DE SÍNTESIS Y LA REDUCCIÓN DEL RIESGO EN COMPARACIÓN CON LAS VACUNAS CONVENCIONALES. EVVIVAX Ê UNA NUEVA EMPRESA QUE (Spanish)
    25 January 2022
    0 references

    Identifiers

    F89J18000160007
    0 references